Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL204687 | 1.00 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL2301332 | 1.00 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL3682796 | 1.00 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL9109080 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL9692462 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL663145 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL9692471 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL663144 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL29391563 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 | |
| Trifluoromethanesulfonic Acid SCHEMBL29253571 | 0.94 | GPR3 (0.39) | GPR3CA1CA2CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116554185-A | Chiral spiro oxindole compound and preparation method thereof | 中国科学技术大学 | 2023-08-08 | — | — | CN | claimed |
| CN-116283923-B | Preparation method of biaryl compound | 杭州师范大学 | 2025-04-11 | — | — | CN | disclosed |
| CN-115141233-B | Synthesis method of rhodium bis (1, 5-cyclooctadiene) triflate | 浙江微通催化新材料有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-116554185-A | Chiral spiro oxindole compound and preparation method thereof | 中国科学技术大学 | 2023-08-08 | — | — | CN | disclosed |
| CN-109661396-B | Spiro-fused cyclic ureas as ROCK inhibitors | 百时美施贵宝公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-114599648-A | Triazole carboxylic acids as LPA antagonists | 百时美施贵宝公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-114599641-A | Cyclobutylcarboxylic acids as LPA antagonists | 百时美施贵宝公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-114599640-A | Isoxazole carboxylic acids as LPA antagonists | 百时美施贵宝公司 | 2022-06-07 | — | — | CN | disclosed |
| EP-2248812-B1 | FUSED CYCLIC COMPOUNDS AS GPR40 RECEPTOR MODULATORS | TAKEDA PHARMACEUTICAL (JP) | 2013-12-25 | — | — | EP | disclosed |
| EP-2041123-B9 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-01-02 | — | — | EP | disclosed |
| EP-2041123-B1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2012-02-01 | — | — | EP | disclosed |
| EP-2248812-A2 | Fused cyclic compounds as GPR40 receptor modulators | Takeda Pharmaceutical Company Limited (JP) | 2010-11-10 | — | — | EP | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2041123-A2 | FUSED CYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008001931-A2 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-03 | — | — | WO | disclosed |
| EP-0153692-B1 | METHOD FOR ISOMERIZATION A GLYCIDATE DERIVATIVE | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1992-07-29 | — | — | EP | disclosed |
| US-4621150-A | METAL PERHALATE OR SULFONATE OR COMPLEX; GLYCIDATE, 2-HYDROXY-3-BUTENOATE, EPOXIDE | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1986-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | GPR3 62/4885CA1 1925/4885CA2 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.